Skip to main content

Acumen Pharmaceuticals, Inc.

ABOS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001576885

No open-market purchases or sales by Acumen Pharmaceuticals, Inc. insiders were filed in the last 90 days; 96 institutions reported holding it in 13F filings for Q2 2026, worth $127.8M in total; no superinvestor holds it.

Q2 2025 vs. Q1 2025

How the institutions holding Acumen Pharmaceuticals, Inc. changed between Q1 2025 and Q2 2025.

All holders in Q2 2025All holders in Q1 2025

13F holders of ABOS: Q1 2025 compared with Q2 2025
MeasureQ1 2025Q2 2025Change
Holders8171−10
Shares40.3M37.6M−2.66M (−6.6%)
Value$44.8M$43.6M−$1.20M (−2.7%)

New holders (17)

Institutions that held Acumen Pharmaceuticals, Inc. at the end of Q2 2025 but not at the end of Q1 2025.

Institutions new to ABOS in Q2 2025
InstitutionSharesValue% of portfolio
Y-Intercept (Hong Kong) Ltd250,848$291.0K0.01%
Marshall Wace, LLP137,943$160.0K0.00%
Jain Global LLC39,990$46.4K0.00%
Gsa Capital Partners LLP32,103$37.0K0.00%
HRT Financial LP31,427$36.0K0.00%
Point72 Asia (Singapore) Pte. Ltd.21,340$24.8K0.00%
Catalyst Funds Management Pty Ltd19,700$22.9K0.01%
Schonfeld Strategic Advisors LLC15,929$18.5K0.00%
Savant Capital, LLC11,045$12.8K0.00%
DRW Securities, LLC11,018$12.8K0.00%
Ethic Inc.11,377$12.7K0.00%
Nisa Investment Advisors, LLC1,229$1.43K0.00%
Skopos Labs, Inc.619$7190.00%
Raymond James Financial Inc495$5740.00%
NBT Bank N A200$2320.00%
Farther Finance Advisors, LLC200$2320.00%
Clearstead Advisors, LLC63$740.00%

Sold out (27)

Institutions that held Acumen Pharmaceuticals, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.